The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
Open accessAbstract
OBJECTIVE: To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies. METHODS: Sera from patients diagnosed with NMOSD in 1 of 3 centers (2 sites in Brazil and 1 site in Japan) were tested for MOG and AQP4 antibodies using cell-based assays with live transfected cells. RESULTS: Among the 215 patients with NMOSD, 7.4% (16/215) were positive for MOG antibodies and 64.7% (139/215) were positive for AQP4 antibodies. No patients were positive for both antibodies. Patients with MOG antibodies represented 21.1% (16/76) of the patients negative for AQP4 antibodies. Compared with patients with AQP4 antibodies or patients who were seronegative, patients with MOG antibodies were more frequently male, had a more restricted phenotype (optic nerve more than spinal cord), more frequently had bilateral simultaneous optic neuritis, more often had a single attack, had spinal cord lesions distributed in the lower portion of the spinal cord, and usually demonstrated better functional recovery after an attack. CONCLUSIONS: Patients with NMOSD with MOG antibodies have distinct clinical features, fewer attacks, and better recovery than patients with AQP4 antibodies or patients seronegative for both antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Panel members agreed that the 2010 McDonald Criteria and 2015 International Panel for NMO Diagnosis Criteria 52 largely distinguish MS and NMOSD, though uncertain cases can occur, particularly with AQP4-seronegative patients.”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
The spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,182
The clinical course of neuromyelitis optica (Devic’s syndrome)
Wingerchuk, D. M., Hogancamp, W. E., O’Brien, P. C., & Weinshenker, B. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1107 · Cited by 1,819
Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre
Takahashi, T., Fujihara, K., Nakashima, I., Misu, T., Miyazawa, I., Nakamura, M., Watanabe, S., Shiga, Y., Kanaoka, C., Fujimori, J., et al. (2007) · Brain · doi:10.1093/brain/awm062 · Cited by 633
Kitley, J., Waters, P., Woodhall, M., Leite, M. I., Murchison, A., George, J., Küker, W., Chandratre, S., Vincent, A., & Palace, J. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5857 · Cited by 597
Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays
Waters, P. J., McKeon, A., Leite, M. I., Rajasekharan, S., Lennon, V. A., Villalobos, A., Palace, J., Mandrekar, J. N., Vincent, A., Bar-Or, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318248dec1 · Cited by 526
Self-citationMader, S., Gredler, V., Schanda, K., Rostasy, K. M., Dujmović, I., Pfaller, K., Lutterotti, A., Jarius, S., Pauli, F. D., Kuenz, B., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-184 · Cited by 449
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
Kitley, J., Woodhall, M., Waters, P., Leite, M. I., Devenney, E., Craig, J., Palace, J., & Vincent, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31826aac4e · Cited by 445
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
O’Connor, K. C., McLaughlin, K. A., Jager, P. L. D., Chitnis, T., Bettelli, E., Xu, C., Robinson, W. H., Cherry, S. V., Bar‐Or, A., Banwell, B., et al. (2007) · Nature Medicine · doi:10.1038/nm1488 · Cited by 419
The spectrum of MOG autoantibody-associated demyelinating diseases
Reindl, M., Pauli, F. D., Rostasy, K. M., & Berger, T. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.118 · Cited by 376
Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica
Misu, T., Fujihara, K., Nakashima, I., Sato, S., & Itoyama, Y. (2005) · Neurology · doi:10.1212/01.wnl.0000183151.19351.82 · Cited by 341
Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
Pröbstel, A., Dornmair, K., Bittner, R., Sperl, P., Jenne, D. E., de Magalhaes, S. L. B., Villalobos, A., Breithaupt, C., Weissert, R., Jacob, U., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c0b1 · Cited by 302
Neuromyelitis optica unique area postrema lesions: Nausea, vomiting, and pathogenic implications
Popescu, B. F. G., Lennon, V. A., Parisi, J. E., Howe, C. L., Weigand, S. D., Cabrera-Gómez, J. A., Newell, K., Mandler, R. N., Pittock, S. J., Weinshenker, B. G., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318214332c · Cited by 296
Acute Fulminant Demyelinating Disease
Seze, J. D., Debouverie, M., Zéphir, H., Lebrun‐Frénay, C., Blanc, F., Bourg, V., Wiertlewski, S., Pittion, S., Laplaud, D. A., Page, E. L., et al. (2007) · Archives of Neurology · doi:10.1001/archneur.64.10.1426 · Cited by 162
The Natural History of Recurrent Optic Neuritis
Pirko, I., Blauwet, L. K., Lesnick, T. G., & Weinshenker, B. G. (2004) · Archives of Neurology · doi:10.1001/archneur.61.9.1401 · Cited by 119
Aquaporin-4 antibody–positive cases beyond current diagnostic criteria for NMO spectrum disorders
Sato, D. K., Nakashima, I., Takahashi, T., Misu, T., Waters, P. J., Kuroda, H., Nishiyama, S., Suzuki, C., Takai, Y., Fujihara, K., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318296ea08 · Cited by 113
Neuro-ophthalmologic evaluation, quality of life, and functional disability in patients with MS
García‐Martín, E., Mena, D. R., Herrero, R., Almárcegui, C., Dolz, I., Martín, J., Ara, J. R., Larrosa, J. M., Polo, V., Fernández, J., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e318299ccd9 · Cited by 69
Relationship Between NMO-Antibody and Anti–MOG Antibody in Optic Neuritis
Kezuka, T., Usui, Y., Yamakawa, N., Matsunaga, Y., Matsuda, R., Masuda, M., Utsumi, H., Tanaka, K., & Gotô, H. (2011) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0b013e31823c9b6c · Cited by 68
Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system
Tanaka, M., & Tanaka, K. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.03.001 · Cited by 59
Atypical presentations of neuromyelitis optica
Sato, D. K., & Fujihara, K. (2011) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2011000600019 · Cited by 38
The two faces of neuromyelitis optica
Weinshenker, B. G., & Wingerchuk, D. M. (2014) · Neurology · doi:10.1212/wnl.0000000000000114 · Cited by 25
Cited by
Sorted by citations
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
Self-citationInternational consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Astrocyte barriers to neurotoxic inflammation
Sofroniew, M. V. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3898 · Cited by 1,202
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F. C., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 900
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Jarius, S., Paul, F., Aktaş, O., Asgari, N., Dale, R. C., Seze, J. D., Franciotta, D. M., Fujihara, K., Jacob, A., Kim, H. J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1144-2 · Cited by 754
Metadata
- Authors
- Sato, D. K., Callegaro, D., Lana-Peixoto, M. A., Waters, P. J., Jorge, F. M. D. H., Takahashi, T., Nakashima, I., Apostolos-Pereira, S. L., Talim, N., Simm, R. F., Lino, A. M. M., Misu, T., Leite, M. I., Aoki, M., & Fujihara, K.
- Affiliations
- Universidade Federal de Minas Gerais (BR)
- From the Departments of Neurology (D.K.S., T.T., I.N., M.A.) and Multiple Sclerosis Therapeutics (T.M., K.F.), Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Neurology (D.C., F.M.d.H.J., S.L.A.-P., R.F.S., A.M.M.L.), Faculty of Medicine, University of São Paulo, Brazil; CIEM MS Research Center (M.A.L.-P., N.T.), Federal University of Minas Gerais Medical School, Belo Horizonte, Brazil; Neuroimmunology Group (P.J.W., M.I.L.), Nuffield Department of Clinical Neurosciences,...
- ORCID
- Venue
- Neurology
- Published
- 2014-02-11
- Volume
- 82
- Issue
- 6
- Pages
- 474-481
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC3937859
- OpenAlex
- W2103812851
- Cited by
- 850
- References
- 21
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 45 · 2023: 67 · 2022: 69 · 2021: 94 · 2020: 95 · 2019: 83 · 2018: 76 · 2017: 82 · 2016: 66 · 2015: 66 · 2014: 38
- FWCI
- 62.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (22229008)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neuromyelitis optica spectrum disorder, anti-MOG antibodies, aquaporin-4 antibodies, seronegative NMOSD, clinical features, optic neuritis, spinal cord lesions, disease phenotypes, functional recovery, relapse rate
- MeSH terms
- Adolescent, Adult, Aged, Autoantibodies, Child, Preschool, Female, Humans, Male, Middle Aged, Neuromyelitis Optica, Phenotype, Sex Factors, Aquaporin 4, Young Adult, Myelin-Oligodendrocyte Glycoprotein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
